{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'b. All events of ALT or AST 3 X ULN and bilirubin > 2 X ULN (> 35% direct bilirubin) or ALT', \"or AST 3 X ULN and INR > 1.5 may indicate severe liver injury (possible 'Hy's Law') and must be\", 'reported as an SAE (excluding studies of hepatic impairment or cirrhosis). The INR stated threshold value', 'will not apply to subjects receiving anticoagulants. INR is not part of routine laboratory assessments in this', 'study.', 'c.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right', 'upper quadrant pain or tenderness, or jaundice) or hypersensitivity (such as fever, rash, or eosinophilia).', 'd.', 'Includes: expanded viral hepatitis serology (Section 10.2 Table 4)', '67', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.7.', 'Appendix 7: Visual Analog scale (VAS)', 'To evaluate the total severity, the subject is asked to indicate on a VAS the answer to the', 'question:', 'How troublesome are your symptoms of rhinosinusitis?', '10 cm', 'Not troublesome', 'Worst thinkable troublesome', 'Example, not for use. Not to scale.', '68', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.8.', 'Appendix 8: ACQ-5 Questionnaire', 'The ACQ-5 questionnaire is located on the following page.', '69', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}